 |
市场调查报告书
商品编码
1898254
生物製药契约製造市场规模、份额和成长分析（按服务、类型、营运规模、原材料、分子类型和地区划分）—产业预测（2026-2033 年）Biopharmaceuticals Contract Manufacturing Market Size, Share, and Growth Analysis, By Service (Manufacturing, Formulation & Fill-Finish), By Type, By Scale Of Operation, By Source, By Molecule Type, By Region - Industry Forecast 2026-2033 |
||||||
全球生物製药契约製造市场预计到 2024 年将达到 178.5 亿美元，到 2025 年将达到 193.2 亿美元，到 2033 年将达到 362.9 亿美元，预测期（2026-2033 年）的复合年增长率为 8.2%。
由于新药研发投资减少、先进技术普及、柔软性增强以及创新产品上市速度加快，全球生物製药契约製造市场预计将显着成长。新建生产设施将提升产能，以满足不断成长的消费者需求。技术进步和创新的生物工艺方法是关键驱动因素，使合约服务供应商能够应对生产成本高昂和批次转移效率低等生产挑战。此外，主要市场参与者之间的策略性收购、合併和联盟正在推动全球对契约製造服务的需求不断增长，从而增强市场成长并扩大生物製药行业的产能。
推动全球生物製药契约製造市场发展的因素
全球生物製药契约製造市场预计将持续成长，这主要得益于几个关键驱动因素，包括学名药需求的持续成长和研发活动的活性化。对先进技术投资的快速成长也促进了市场扩张。此外，生物疗法需求的成长以及核医领域的进步预计将进一步增强市场动态。特药日益增长的重要性巩固了这一上升趋势，为全球生物製药行业的研发和创新奠定了坚实的基础，这有望在不久的将来改变市场格局。
限制全球生物製药契约製造市场的因素
全球生物製药契约製造市场面临许多挑战，可能阻碍其成长。其中，生产流程中的关键问题，特别是标籤不一致、包装复杂和灭菌困难等，构成了重大障碍。此外，消费者信任度不足以及对生产流程缺乏了解也可能阻碍市场扩张。这些因素共同创造了一个不利于产业内潜在投资和合作的环境，最终影响生物製药契约製造的整体发展和成功。相关人员需要解决这些问题，以创造更好的成长环境并增强市场信心。
生物製药契约製造市场的全球趋势
在全球生物製药契约製造市场中，受技术进步和科学探索不断深入的推动，市场呈现稳定上升的趋势。人工智慧（AI）在生产现场的日益普及，提高了营运效率，并能够更精准地分析复杂的生物过程和患者数据。这项技术变革不仅简化了生产週期，还有助于实现个人化医疗，以满足多样化的治疗需求。随着相关人员日益认识到人工智慧驱动的创新在优化药物研发和生产流程方面的潜力，在对高效生物製药解决方案需求不断增长的推动下，预计该市场将实现显着增长。
目录
介绍
- 调查目标
- 调查范围
- 定义
调查方法
- 资讯收集
- 二手资料和一手资料方法
- 市场规模预测
- 市场假设与限制
执行摘要
- 全球市场展望
- 供需趋势分析
- 细分市场机会分析
市场动态与展望
- 市场规模
- 市场动态
- 驱动因素和机会
- 限制与挑战
- 波特分析
关键市场考察
- 关键成功因素
- 竞争程度
- 关键投资机会
- 市场生态系统
- 市场吸引力指数（2025）
- PESTEL 分析
- 总体经济指标
- 价值链分析
- 定价分析
- 技术分析
- 监管分析
- 专利分析
- 案例研究
- 经FDA核准的生物製药契约製造组织（CMO）中心
全球生物製药契约製造市场规模（依服务类型划分）及复合年增长率（2026-2033 年）
- 製造业
- 配方、填充和成品
- 包装/展示
- 其他服务
全球生物製药契约製造市场规模（按类型和复合年增长率划分）（2026-2033 年）
- 生技製药原料药生产
- 生物製药生产
全球生物製药契约製造市场规模（按营运规模和复合年增长率划分）（2026-2033 年）
- 商业营运
- 临床操作
全球生物製药契约製造市场规模（按材料和复合年增长率划分）（2026-2033 年）
- 哺乳动物表达系统
- 非哺乳动物表达系统
全球生物製药契约製造市场规模（按分子类型划分）及复合年增长率（2026-2033 年）
- 单株抗体
- 细胞和基因治疗
- 抗体药物复合体
- 疫苗
- 治疗性胜肽和蛋白质
- 其他分子类型
全球生物製药契约製造市场规模（依治疗领域划分）及复合年增长率（2026-2033 年）
- 肿瘤学
- 自体免疫疾病
- 代谢性疾病
- 循环系统疾病
- 神经病学
- 感染疾病
- 其他治疗领域
全球生物製药契约製造市场规模及复合年增长率（2026-2033）
- 北美洲
- 美国
- 加拿大
- 欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
- 亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
- 拉丁美洲
- 巴西
- 其他拉丁美洲地区
- 中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区
竞争资讯
- 前五大公司对比
- 主要企业的市场定位（2025 年）
- 主要市场参与者所采取的策略
- 近期市场趋势
- 公司市占率分析（2025 年）
- 主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较
主要企业简介
- Lonza（Switzerland）
- Thermo Fisher Scientific Inc.（US）
- WuXi Biologics（China）
- Catalent, Inc.（US）
- Samsung Biologics（South Korea）
- Boehringer Ingelheim International GmbH（Germany）
- Fujifilm Holdings Corporation（Japan）
- AbbVie Inc.（US）
- Eurofins Scientific（Luxembourg）
- GenScript Biotech Corporation（China）
- AGC Inc.（Japan）
- Merck
- KGaA（Germany）
- JSR Corporation（Japan）
- Stelis（India）
- Recipharm AB（Sweden）
- Emergent（US）
- Shanghai Fosun Pharmaceutical Co., Ltd.（China）
- Lotte Biologics（South Korea）
- Hepalink Group（China）
- Curia Global, Inc.（US）
结论与建议
Global Biopharmaceuticals Contract Manufacturing Market size was valued at USD 17.85 Billion in 2024 and is poised to grow from USD 19.32 Billion in 2025 to USD 36.29 Billion by 2033, growing at a CAGR of 8.2% during the forecast period (2026-2033).
The global biopharmaceutical contract manufacturing market is poised for significant growth due to reduced investment for new drug development, access to advanced technologies, increased flexibility, and expedited market entry for innovative products. The establishment of new manufacturing facilities enhances production capacity to meet the rising consumer demand. Technological advancements and innovative bioprocessing methods are key drivers, enabling contract service providers to address manufacturing challenges such as high production costs and efficiency during batch transitions. Additionally, strategic acquisitions, mergers, and collaborations among prominent market players are fostering increased demand for contract manufacturing services worldwide, reinforcing market growth and expanding capabilities within the biopharmaceutical sector.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biopharmaceuticals Contract Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Biopharmaceuticals Contract Manufacturing Market Segments Analysis
Global Biopharmaceuticals Contract Manufacturing Market is segmented by Service, Type, Scale Of Operation, Source, Molecule Type,TherapeuticArea and region. Based on Service, the market is segmented into Manufacturing, Formulation & Fill-Finish, Packaging & Labeling and Other Services. Based on Type, the market is segmented into Biologic Drug Substance Manufacturing and Biologic Drug Product Manufacturing. Based on Scale Of Operation, the market is segmented into Commercial Operations and Clinical Operations. Based on Source, the market is segmented into Mammalian Expression Systems and Non-Mammalian Expression Systems. Based on Molecule Type, the market is segmented into Monoclonal Antibodies, Cell & Gene Therapies, Antibody-Drug Conjugates, Vaccines, Therapeutic Peptides & Proteins and Other Molecule Types. Based on Therapeutic Area, the market is segmented into Oncology, Autoimmune Diseases, Metabolic Diseases, Cardiovascular Diseases, Neurology, Infectious Diseases and Other Therapeutic Areas. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Biopharmaceuticals Contract Manufacturing Market
The global biopharmaceuticals contract manufacturing market is poised for growth due to several key drivers, including the persistent increase in demand for generics and escalating research and development activities. A surge in investments focused on advanced technologies also contributes to market expansion. Additionally, the rising need for biological therapies, coupled with advancements in the nuclear medicine sector, is expected to further enhance market dynamics. The growing emphasis on specialty medicines serves to solidify this upward trajectory, positioning the global biopharmaceuticals landscape for robust development and innovation, which will likely transform the market in the foreseeable future.
Restraints in the Global Biopharmaceuticals Contract Manufacturing Market
The global biopharmaceuticals contract manufacturing market faces several challenges that may hinder its growth. Key issues related to the manufacturing process, including labeling inconsistencies, packaging complications, and difficulties in sterilization, are significant obstacles. Furthermore, a lack of consumer trust and limited knowledge regarding the manufacturing processes could also impede the market's expansion. These factors contribute to an environment that may deter potential investments and partnerships within the industry, ultimately affecting the overall development and success of biopharmaceutical contract manufacturing. Stakeholders must address these concerns to foster a more favorable growth landscape and enhance market confidence.
Market Trends of the Global Biopharmaceuticals Contract Manufacturing Market
The global biopharmaceuticals contract manufacturing market is witnessing a robust upward trend fueled by advancements in technology and increased scientific exploration. The growing integration of artificial intelligence (AI) within the manufacturing landscape is enhancing operational efficiencies, allowing for more accurate analysis of complex biological processes and patient data. This technological shift not only streamlines production cycles but also facilitates personalized medicine approaches, catering to a diverse range of therapeutic needs. As stakeholders increasingly recognize the potential of AI-driven innovations in optimizing drug development and manufacturing processes, the market is poised for significant growth, driven by rising demand for effective biopharmaceutical solutions.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2025
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Technology Analysis
- Regulatory Analysis
- Patent Analysis
- Case Studies
- FDA Approved Biopharmaceuticals CMOs Centers
Global Biopharmaceuticals Contract Manufacturing Market Size by Service & CAGR (2026-2033)
- Market Overview
- Manufacturing
- Formulation & Fill-Finish
- Packaging & Labeling
- Other Services
Global Biopharmaceuticals Contract Manufacturing Market Size by Type & CAGR (2026-2033)
- Market Overview
- Biologic Drug Substance Manufacturing
- Biologic Drug Product Manufacturing
Global Biopharmaceuticals Contract Manufacturing Market Size by Scale Of Operation & CAGR (2026-2033)
- Market Overview
- Commercial Operations
- Clinical Operations
Global Biopharmaceuticals Contract Manufacturing Market Size by Source & CAGR (2026-2033)
- Market Overview
- Mammalian Expression Systems
- Non-Mammalian Expression Systems
Global Biopharmaceuticals Contract Manufacturing Market Size by Molecule Type & CAGR (2026-2033)
- Market Overview
- Monoclonal Antibodies
- Cell & Gene Therapies
- Antibody-Drug Conjugates
- Vaccines
- Therapeutic Peptides & Proteins
- Other Molecule Types
Global Biopharmaceuticals Contract Manufacturing Market Size by Therapeutic Area & CAGR (2026-2033)
- Market Overview
- Oncology
- Autoimmune Diseases
- Metabolic Diseases
- Cardiovascular Diseases
- Neurology
- Infectious Diseases
- Other Therapeutic Areas
Global Biopharmaceuticals Contract Manufacturing Market Size & CAGR (2026-2033)
- North America (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
- US
- Canada
- Europe (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
- Brazil
- Rest of Latin America
- Middle East & Africa (Service, Type, Scale Of Operation, Source, Molecule Type, Therapeutic Area)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Lonza (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Catalent, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Biologics (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fujifilm Holdings Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Scientific (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GenScript Biotech Corporation (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AGC Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- JSR Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Stelis (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Recipharm AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Emergent (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shanghai Fosun Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lotte Biologics (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hepalink Group (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Curia Global, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
即用型 (RTU) 药品包装市场（第三版）：产业趋势及全球预测（至 2035 年）－依容器类型、封盖类型、製造材料和主要地区划分抗体药物偶联物 (ADC) 合约生产市场（第七版）：依研发阶段、製程组件、有效载荷、抗体同型、标靶适应症、抗体来源、连接子和主要地区划分——产业趋势及全球预测至 2035 年
生物製药CMO/CRO市场规模、份额和成长分析（按供应来源、服务类型、产品和地区划分）－产业预测（2026-2033年）最后填充医药品受託製造市场:2035年前的产业趋势和全球预测 - 各最后填充服务形式，FDF，API滴定率，一次用包装容器，各地区，主要企业
即用型药品包装市场分析及预测（至2034年）：类型、产品、服务、技术、材料类型、应用、设备、最终用户、流程、解决方案
医疗保健契约製造市场按服务类型、产品类型、分子类型、治疗领域、最终用户和公司规模划分－全球预测，2025-2032年医药契约製造和研发服务市场（按服务类型和最终用户划分）－2025-2032年全球预测医药契约製造市场按服务类型、分子类型、剂型、客户类型、治疗领域、合约类型、製造规模和製程类型划分 - 全球预测，2025-2032 年合约研究与生产服务市场（按服务类型、技术、治疗领域、应用和最终用户划分）—2025-2032年全球预测抗体契约製造市场：下游－2025-2032年全球预测